STAAR Surgical Company (STAA) Key Metrics
STAA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.07B
- Enterprise value
- $1.20B
- P/E (TTM)
- 265.9 10-yr median 140.8
- Forward P/E
- 62.5
- PEG ratio
- 0.76
- Price / sales
- 3.1 10-yr median 7.7
- Price / book
- 4.0 10-yr median 10.6
- EV / EBITDA
- 42.8 10-yr median 111.6
- Dividend yield
- —
- Beta
- 1.18
STAA key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSTAA valuation Price multiples at each fiscal year-end price.
STAA returns How much profit the business earns on the capital it uses.
STAA per-share figures Results divided by the shares outstanding at year-end.
STAA financial health Debt, liquidity and how easily interest is covered.
STAA efficiency & capital use Working capital cycle and where the cash goes.
STAA valuation history
STAA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
STAA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
STAA cash returned to shareholders
STAA price vs earnings per share
STAA key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.14B | $1.19B | $1.54B | $2.40B | $4.52B | $3.80B | $1.65B | $1.44B | $635.6M | $437.6M |
| Enterprise value | $995.3M | $1.00B | $1.36B | $2.22B | $4.35B | $3.66B | $1.54B | $1.35B | $623.3M | $430.4M |
| P/E ratio | — | — | 72.3 | 60.4 | 164.1 | 642.5 | 117.4 | 290.7 | — | — |
| Price / sales | 4.8 | 3.8 | 4.8 | 8.4 | 19.6 | 23.2 | 11.0 | 11.7 | 7.0 | 5.3 |
| Price / book | 3.3 | 3.0 | 4.0 | 7.1 | 17.5 | 19.3 | 10.3 | 10.9 | 14.8 | 11.5 |
| Price / free cash flow | — | — | — | 136.1 | 148.9 | 302.8 | 105.6 | 137.3 | 351.7 | — |
| Price / operating cash flow | — | 75.9 | 105.7 | 67.1 | 102.7 | 181.3 | 63.9 | 113.1 | 222.8 | 417.1 |
| EV / sales | 4.2 | 3.2 | 4.2 | 7.8 | 18.9 | 22.4 | 10.2 | 10.9 | 6.9 | 5.2 |
| EV / EBITDA | — | — | 35.0 | 44.3 | 124.3 | 370.8 | 99.0 | 148.5 | — | — |
| EV / free cash flow | — | — | — | 125.9 | 143.4 | 291.5 | 98.5 | 127.9 | 344.9 | — |
| Earnings yield | −7.0% | −1.7% | 1.4% | 1.7% | 0.6% | 0.2% | 0.9% | 0.3% | −0.3% | −2.8% |
| Free cash flow yield | −3.5% | −0.6% | −0.2% | 0.7% | 0.7% | 0.3% | 0.9% | 0.7% | 0.3% | −0.5% |
| Dividend yield | — | — | 0.0% | — | — | — | — | 0.4% | 0.6% | 0.9% |
| Shareholder yield (dividends + buybacks) | 0.6% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.7% | 1.0% |
| Share price at fiscal year-end | $23.09 | $24.29 | $31.21 | $48.54 | $91.30 | $79.22 | $35.17 | $31.91 | $15.50 | $10.85 |
| Per share | ||||||||||
| Revenue per share | $4.83 | $6.39 | $6.52 | $5.76 | $4.66 | $3.41 | $3.20 | $2.74 | $2.21 | $2.04 |
| Earnings per share | −$1.62 | −$0.41 | $0.43 | $0.80 | $0.56 | $0.12 | $0.30 | $0.11 | −$0.05 | −$0.30 |
| Operating cash flow per share | −$0.69 | $0.32 | $0.30 | $0.72 | $0.89 | $0.44 | $0.55 | $0.28 | $0.07 | $0.03 |
| Free cash flow per share | −$0.81 | −$0.16 | −$0.07 | $0.36 | $0.61 | $0.26 | $0.33 | $0.23 | $0.04 | −$0.05 |
| Cash per share | $3.78 | $4.69 | $4.47 | $4.29 | $4.04 | $3.18 | $2.56 | $2.30 | $0.45 | $0.35 |
| Book value per share | $6.94 | $8.09 | $7.81 | $6.81 | $5.23 | $4.11 | $3.41 | $2.93 | $1.05 | $0.94 |
| Tangible book value per share | $6.29 | $7.73 | $7.77 | $6.77 | $5.19 | $4.07 | $3.37 | $2.88 | $1.00 | $0.88 |
| Dividends per share | — | — | $0.00 | — | — | — | — | $0.11 | $0.10 | $0.10 |
| Capex per share | $0.12 | $0.48 | $0.37 | $0.37 | $0.28 | $0.18 | $0.22 | $0.05 | $0.03 | $0.08 |
| Debt per share | $0.77 | $0.79 | $0.72 | $0.63 | $0.65 | $0.23 | $0.20 | $0.12 | $0.15 | $0.17 |
| Shares outstanding | 49.6M | 49.1M | 49.4M | 49.4M | 49.5M | 48.0M | 46.9M | 45.3M | 41.0M | 40.3M |
| Change in shares outstanding | +0.9% | −0.6% | +0.1% | −0.2% | +3.1% | +2.3% | +3.6% | +10.4% | +1.7% | +2.7% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −21.7% | −5.2% | 5.9% | 13.3% | 12.1% | 3.3% | 9.6% | 5.7% | −5.3% | −31.6% |
| Return on invested capital (ROIC) | −18.1% | −4.9% | 10.0% | 31.0% | 40.0% | 9.2% | 28.4% | 15.3% | −9.3% | −32.8% |
| Return on assets (ROA) | −16.6% | −4.0% | 4.7% | 10.4% | 9.1% | 2.5% | 7.5% | 4.2% | −3.2% | −18.9% |
| Return on tangible assets | −18.7% | −4.1% | 4.4% | 9.5% | 8.0% | 2.3% | 6.8% | 3.0% | −3.2% | −19.2% |
| Free cash flow margin | −16.7% | −2.4% | −1.1% | 6.2% | 13.2% | 7.7% | 10.4% | 8.5% | 2.0% | −2.6% |
| Income quality (OCF / net income) | — | — | 0.68 | 0.90 | 1.60 | 3.54 | 1.84 | 2.57 | — | — |
| Financial health | ||||||||||
| Total debt | $38.4M | $38.7M | $35.8M | $31.0M | $32.1M | $10.8M | $9.5M | $5.3M | $6.2M | $6.8M |
| Cash & short-term investments | $187.5M | $230.5M | $220.7M | $211.6M | $199.7M | $152.5M | $120.0M | $103.9M | $18.5M | $14.0M |
| Net debt | −$149.2M | −$191.8M | −$184.9M | −$180.6M | −$167.6M | −$141.7M | −$110.4M | −$98.5M | −$12.3M | −$7.2M |
| Debt / equity | 0.11 | 0.10 | 0.09 | 0.09 | 0.12 | 0.05 | 0.06 | 0.04 | 0.15 | 0.18 |
| Debt / assets | 0.08 | 0.08 | 0.07 | 0.07 | 0.09 | 0.04 | 0.05 | 0.03 | 0.09 | 0.10 |
| Net debt / EBITDA | — | — | −4.76 | −3.61 | −4.79 | −14.36 | −7.10 | −10.88 | — | — |
| Current ratio | 4.55 | 5.23 | 5.62 | 6.03 | 5.56 | 5.25 | 5.07 | 5.47 | 2.82 | 2.37 |
| Quick ratio | 3.74 | 4.62 | 5.08 | 5.56 | 5.21 | 4.81 | 4.57 | 4.86 | 2.13 | 1.67 |
| Interest coverage | — | — | — | 17.9 | 877.3 | 2.9 | 18.0 | 40.0 | -32.4 | -110.0 |
| Working capital | $243.0M | $297.6M | $300.2M | $260.0M | $222.6M | $175.2M | $140.2M | $123.8M | $34.8M | $28.8M |
| Invested capital | $195.0M | $205.6M | $201.1M | $155.5M | $90.9M | $55.6M | $49.5M | $33.9M | $30.7M | $30.7M |
| Tangible asset value | $311.7M | $379.8M | $384.2M | $334.2M | $256.6M | $195.2M | $157.8M | $130.4M | $40.9M | $35.6M |
| Net current asset value | $194.1M | $255.8M | $262.5M | $229.0M | $184.2M | $156.2M | $127.0M | $116.7M | $28.9M | $22.4M |
| Graham number | — | — | $8.71 | $11.09 | $8.09 | $3.38 | $4.79 | $2.69 | — | — |
| Graham net-net per share | $2.80 | $4.06 | $4.23 | $3.86 | $3.16 | $2.66 | $2.25 | $2.14 | $0.33 | $0.15 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $9,673 | — | — | — | — | $5.2M | $4.0M | $4.0M |
| Share buybacks (net) | $6.5M | $1.5M | $2.1M | $0 | $0 | $0 | $0 | $54,000 | $234,000 | $611,000 |
| Dividend payout ratio | — | — | 0.0% | — | — | — | — | 104.6% | — | — |
| Dividends + buybacks / free cash flow | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 49.9% | 232.6% | — |
| Capex / revenue | 2.4% | 7.5% | 5.6% | 6.4% | 5.9% | 5.1% | 6.8% | 1.8% | 1.2% | 3.9% |
| Capex / operating cash flow | — | 148.8% | 124.6% | 50.7% | 31.0% | 40.1% | 39.5% | 17.6% | 36.7% | 305.5% |
| Capex / depreciation | 0.70 | 3.39 | 3.55 | 4.02 | 3.75 | 2.72 | 2.75 | 0.91 | 0.31 | 1.11 |
| Stock-based compensation / revenue | 12.8% | 8.7% | 7.3% | 7.2% | 6.3% | 7.4% | 7.0% | 5.5% | 3.5% | 10.4% |
| R&D / revenue | 16.7% | 17.2% | 13.8% | 12.7% | 14.7% | 19.5% | 16.8% | 17.8% | 21.1% | 24.6% |
| SG&A / revenue | 78.6% | 63.1% | 55.9% | 50.5% | 48.4% | 48.7% | 49.8% | 50.7% | 53.9% | 61.5% |
| Efficiency | ||||||||||
| Days sales outstanding | 102.0 | 103.0 | 92.8 | 72.2 | 64.8 | 75.7 | 71.1 | 64.5 | 68.9 | 70.9 |
| Days of inventory on hand | 316.2 | 192.6 | 155.1 | 123.9 | 124.6 | 142.7 | 161.6 | 168.8 | 195.0 | 233.2 |
| Days payables outstanding | 90.5 | 74.3 | 65.7 | 60.7 | 40.5 | 44.0 | 69.6 | 70.6 | 99.4 | 113.8 |
| Cash conversion cycle (days) | 327.7 | 221.3 | 182.2 | 135.5 | 148.8 | 174.4 | 163.1 | 162.7 | 164.5 | 190.3 |
| Receivables turnover | 3.58 | 3.54 | 3.93 | 5.05 | 5.64 | 4.82 | 5.13 | 5.66 | 5.30 | 5.15 |
| Payables turnover | 4.03 | 4.91 | 5.55 | 6.02 | 9.00 | 8.30 | 5.25 | 5.17 | 3.67 | 3.21 |
| Inventory turnover | 1.15 | 1.90 | 2.35 | 2.94 | 2.93 | 2.56 | 2.26 | 2.16 | 1.87 | 1.57 |
| Asset turnover | 0.49 | 0.63 | 0.71 | 0.74 | 0.76 | 0.70 | 0.80 | 1.05 | 1.36 | 1.28 |
| Average receivables | $66.9M | $88.6M | $82.0M | $56.3M | $40.9M | $33.9M | $29.3M | $21.9M | $17.1M | $16.0M |
| Average payables | $14.1M | $15.1M | $12.6M | $10.1M | $5.8M | $5.4M | $7.3M | $6.3M | $7.2M | $7.5M |
| Average inventory | $49.4M | $39.2M | $29.6M | $20.7M | $17.7M | $17.6M | $16.9M | $15.0M | $14.1M | $15.4M |
| Intangibles / total assets | 7.0% | 3.4% | 0.4% | 0.5% | 0.6% | 0.8% | 1.0% | 1.2% | 3.0% | 3.5% |
Computed from STAA's annual financial statements (latest annual report filed March 3, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
STAA valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 265.9 and the forward P/E is 62.5. STAAR Surgical earned a return on equity of −21.7% and a return on invested capital of −18.1% in fiscal 2025. It ended the year with $38.4 million of debt and $187.5 million in cash and short-term investments, a net cash position of $149.2 million. It returned $6.5 million to shareholders: $0 in dividends and $6.5 million in share buybacks. The share count rose 22.9% from 40.3M to 49.6M over 9 years.
See the STAA income statement, the STAA chart for price history, or the STAA stock overview for the latest quote and news.
STAA key metrics FAQ
What is STAAR Surgical's P/E ratio?
STAAR Surgical's trailing P/E ratio is 265.9 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 62.5. At the end of fiscal 2025 it was —, compared with a 10-year median of 140.8.
What is STAAR Surgical's return on equity?
STAAR Surgical's return on equity (ROE) was −21.7% in fiscal 2025: net income of -$80.4 million on average shareholders' equity of $370.8 million.
What is STAAR Surgical's ROIC?
STAAR Surgical's return on invested capital was −18.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does STAAR Surgical have?
STAAR Surgical had total debt of $38.4 million at the end of fiscal 2025, a debt-to-equity ratio of 0.11 and more cash than debt.
Does STAAR Surgical buy back its shares?
Yes. STAAR Surgical spent $6.5 million on net share repurchases in fiscal 2025 Shares outstanding changed +0.9% over the year, to 49.6M..
What is STAAR Surgical's free cash flow yield?
STAAR Surgical generated -$40.0 million of free cash flow in fiscal 2025, a free cash flow yield of −3.5% on its market value at year-end ($1.1 billion).
What is STAAR Surgical's current ratio?
STAAR Surgical's current ratio was 4.55 at the end of fiscal 2025: current assets were 4.55 times current liabilities.